Programmed Cell Death 1 Ligand 2 Proteins (PDCD1LG2)

Pig (Porcine) Programmed Cell Death 1 Ligand 2 (PDCD1LG2) interaction partners

1. These data suggest that overexpression of PD-L1 and PD-L2 mRNA is one mechanism by which immunosupression of postweaning multisystemic wasting syndrome pigs occurs.

Human Programmed Cell Death 1 Ligand 2 (PDCD1LG2) interaction partners

1. The data indicate that a genetically determined individual difference in a non-synonymous missense SNP of PD-L2 might influence the susceptibility to chronic lymphatic filariasis in a South Indian population.

2. A subset of ocular invasive conjunctival squamous carcinomas express high levels of PD-L1 and CD8 and therefore may respond therapeutically to immune checkpoint inhibition.

3. High frequency of PD-L2 involving genetic aberrations was associated with EBV-positive lymphomas.

4. Low PD-L2 expression is associated with Lung Adenocarcinoma.

5. FISH technique and qPCR data coupled with immunofluorescence revealed that genetic alterations of 9p24.1 robustly contributed to PD-L1 and PD-L2 upregulation. In addition, increased expression of PD-L1 instead of PD-L2 also predicted poor survival by multivariate analyses. Meanwhile, high infiltration of PD-1(+) immune cells also indicated dismal survival in hepatocellular carcinoma.

6. PD-1, PD-L1 and PD-L2 were differentially expressed between primary and metastatic tumors. Histopathological examination of these immune check points in metastatic lesions of mRCC should be noticed, and its accurate diagnosis may be one of the effective ways to realize the individualized treatment.

7. we noticed that chronic inflammation of colonic mucosa may lead to up-regulation of PD-L1 and -L2 expression in patients with UC, which may result in regulation of immune responses against this chronic inflammation and then prevent progressive and acute inflammation of the disease.

8. Studied expression levels of PDCD1 ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2) in patients with hematologic malignancies.

9. HOXC10 directly binds to the PD-L2 and TDO2 promoter regions thus stimulating proliferation, invasion and induction of immunosuppressive gene expression in glioma.

10. soluble PD-1 ligands are elevated in Waldenstrom macroglobulinemia (WM) patients and, in addition to surface-bound ligands in WM BM, could regulate T-cell function. Given the capability of secreted forms to be bioactive at distant sites, soluble PD-1 ligands have the potential to promote disease progression in WM.

11. PDCD1LG2 (PD-L2) RNA in situ hybridization is a sensitive, specific, and practical marker of primary mediastinal large B-cell lymphoma.

12. PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type.

13. PD-L2-positive lung adenocarcinomas are less radiologically malignant and invasive than their PD-L1-positive counterparts

14. Our results confirm and extend prior studies of PD-L1 and provide new data of PD-L2 expression in lymphomas

15. High PD-L2 expression may be a target of immunotherapy in patients with PD-L1-negative Non-small Cell Lung Cancer.

16. The high-affinity PD-1 mutant could compete with the binding of antibodies specific to PD-L1 or PD-L2 on cancer cells.

17. the binding affinities of the PD-1-PD-L1/PD-L2 co-inhibitory receptor system, was characterized.

18. Tumor PDCD1LG2 expression is inversely associated with Crohn-like lymphoid reaction to colorectal cancer, suggesting a possible role of PDCD1LG2-expressing tumor cells in inhibiting the development of tertiary lymphoid tissues during colorectal carcinogenesis.

19. The biopsy tumor key protein measurements demonstrate substantial between-tumor variation in expression ratios of these proteins and suggest that programmed cell death 1 ligand 2 PD-L2 is present in some tumors at levels sufficient to contribute to programmed cell death-1 PD-1-dependent T-cell regulation and possibly to affect responses to PD-1- and programmed cell death 1 ligand 1 PD-L1-blocking drugs.

20. the positive rate of PD-L2 did not show any differences between primary tumors and metastatic lymph nodes. In multivariate analysis, PD-L1 expression, PD-L2 expression, a low density of CD8(+) T cells in primary tumors, and PD-1 expression on CD8(+) T cells in primary tumors were associated with poor prognosis.

Mouse (Murine) Programmed Cell Death 1 Ligand 2 (PDCD1LG2) interaction partners

1. that aspects of liver dysfunction increase in septic mice lacking the PD-L2 gene

2. acute loss of BCL6 in germinal center B cells led to remarkable upregulation of mRNA and protein abundance of PD-L1 and PD-L2

3. These findings from the K113S variant provide not only a possible explanation for the B7-DC-triggered contradictory effects on T-cell responses, but also a novel approach to investigate the B7-DC/PD-1/RGMb axis.

4. Data suggest that programmed cell death 1 ligand 2 (PD-L2)'s function becomes evident when the effects of programmed cell death 1 ligand 1 (PD-L1) are abrogated.

5. Data demonstrates that during Fasciola hepatica infection, the PD-L2 signaling pathway is involved in alternative macrophage polarization as well as in the control of the underlying Th1-type immune response, and concomitantly plays a key role in determining the susceptibility to this heminth infection.

6. PD-L1 and PD-L2 in dermal fibroblasts is up-regulated by activated T cells in alopecia areata-affected skin.

7. this study demonstrates that PD-L2 regulates the production of natural Abs against phosphorylcholine

8. findings indicate that the PerC B cells, including PD-L1/PD-L2 B-1a cells, may suppress T cells responding to allostimulation, and thus may be optimal for donor lymphocyte injection

9. this study shows that PD-L2 is essential for effective CD4+ T cell immunity and determines the severity of malarial infections

10. injection of gene knockdown-dendritic cells induces intra-tumor T cell infiltration and release of inflammatory cytokines

11. The endogenous PD-1/PD-L pathway does not limit acute experimental foreign antigen-induced circulating immune complex glomerulonephritis.

12. PD-L1 and PD-L2 are nonredundant aspects of the natural protective response to ischemic injury and may be novel therapeutic targets for Acute kidney injury.

13. long-term use of indomethacin leads to poor prognoses through promoting the expression of PD-1 and PD-L2.

14. TLR2 signaling can direct PD-L2 expression on dendritic cells, which binds to PD-1 mainly on CD4(+)T cells, to help inhibit T cells response in Schistosoma japonicum infection.

15. This study reveals DOK3 as a nonredundant regulator of plasma cell differentiation by up-regulating PD-1 ligand expression through the attenuation of calcium signaling.

16. demonstrate that subcategorizing memory B cells on the basis of their expression of CD80 and PD-L2

17. In vivo T cell activation induces the formation of CD209(+) PDL-2(+) dendritic cells.

18. Blockade of PD-L2 and RGMb interaction prevented the development of respiratory tolerance

19. Endogenous IL-21, therefore, has potent and specific effects on mucosal antiviral responses, assisting viral clearance, regulating pulmonary T- and B-cell responses, and inhibiting IL-17 production.

20. Host PD-L1 is dominant over PD-L2 expression in regulating graft-versus-host disease lethality.